by The middle east and Asia Pacific cell and gene therapy market is comprised of life-saving therapeutics used in treating cancer and rare genetic diseases. These advanced therapies work by delivering genetic material into a patient’s cells to produce or regulate a therapeutic protein. Cell therapies involve removing cells from a patient’s body, modifying them to fight diseases, and reintroducing them into the body. Gene therapies alter genes to compensate or correct genetic defects. With rising cases of cancer, demand for these transformative treatments in oncology and hematology is growing.
The global middle east and Asia Pacific cell and gene therapy market is estimated to be valued at US$ 4147.82 Th in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2030.
Key Takeaways
Key players: Key players operating in the middle east and Asia Pacific cell and gene therapy market are BASF SE, Croda Health Care, JRS Pharma, Lipoid GmbH, Azelis, U.K. Vet Chem, Gattefoss, Synergy API, Anzchem, Vantage. These companies are investing heavily in R&D to develop new cell and gene therapies for various therapeutic areas.
Key opportunities: Increasing healthcare spending in middle eastern and Asian countries, strong biotech industry ecosystem, and supportive regulations provide huge opportunities for growth of cell and gene therapies in the region. Also, growing emphasis on personalized medicine and cell-based immunotherapy open lucrative avenues.
Global expansion: Major players are expanding their manufacturing facilities and clinical trial infrastructure in Asia Pacific and middle eastern countries. Strategic partnerships between global drug makers and local biosimilar companies are also supporting the global expansion of the cell and gene therapy market in the region.
Market Drivers
Rising healthcare expenditure in countries like India, China, Saudi Arabia is a key growth driver as it enables more affordable access to these highly priced therapies. Furthermore, expansion of the biopharmaceutical industry, presence of leading gene and cell therapy research institutes, and growing R&D investments from governments and pharma companies are fueling the middle east and Asia Pacific cell and gene therapy market.
PEST Analysis
Political: The regulatory authorities in the Global Middle East And Asia Pacific Cell And Gene Therapy Market Growth region are supporting the cell and gene therapy market through various initiatives. However, the regulations regarding clinical trials and product approvals vary across countries which can impact the growth.
Economic: The rising healthcare expenditure and increasing disposable incomes in the emerging economies of Asia Pacific is driving the growth of the cell and gene therapy market in the region.
Social: With growing awareness about cell and gene therapies, people are willing to opt for such advanced treatment options for various incurable diseases. This is positively impacting the market growth.
Technological: Development of advanced treatment procedures and focus on manufacturing techniques to reduce costs is supporting the market growth. Companies are investing in R&D to develop customized therapies using latest technologies like CRISPR.
Geographical Regions with High Market Concentration
The Middle East region holds a significant share of the overall cell and gene therapy market in terms of value, primarily driven by countries like Saudi Arabia and UAE. This is attributed to high healthcare spending and presence of leading market players in these countries.
Fastest Growing Region
Asia Pacific region is expected to witness the fastest growth during the forecast period owing to rise in incidence of chronic diseases, improving healthcare infrastructure and increasing government funding for medical research in emerging nations like China, India and South Korea
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
